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Objective: Placental cytogenetic studies may reveal the origin of discordant nonin-
vasive prenatal testing (NIPT). We performed placental studies to elucidate discor-
dances between NIPT showing a structural chromosome aberration and the fetus
having a different chromosome aberration in three cases.
Method: Diagnostic testing with genomic SNP microarray was performed in three
cases with NIPT showing a duplication on 4q (case 1), a terminal deletion of 13q (case
2), and a terminal deletion of 15q (case 3). Placental studies involved SNP array anal-
ysis of cytotrophoblast and mesenchymal core of chorionic villi of four placental
quadrants. Clinical follow‐up was performed as well.
Results: Amniotic fluid revealed a different structural chromosome aberration than
predicted by NIPT: a terminal 2q deletion (case 1), a segmental uniparental isodisomy
of 13q (case 2), and a terminal duplication of 15q and of 13q (case 3). Placental stud-
ies revealed the aberration detected with NIPT in the cytotrophoblast, whereas the
fetal karyotype was confirmed in the placental mesenchymal core.
Conclusion: Our study shows that targeted cytogenetic investigations for confir-
mation of NIPT showing a microscopically visible structural chromosome aberration
should be avoided, since another aberration, even a submicroscopic one or one
involving another chromosome, may be present in the fetus.1 | INTRODUCTION
Noninvasive prenatal testing (NIPT) like other prenatal screening
methods has focused on the detection of the most common chromo-
some aberrations, trisomies 21, 18, and 13, with or without sex‐- - - - - - - - - - - - - - - - - - - - - - - - - -
Creative Commons Attribution Li
by John Wiley & Sons, Ltd.chromosomal aneuploidies. However, by using genome‐wide sequenc-
ing or an array approach, other fetal chromosome aberrations such as
other autosomal trisomies as well as structural chromosome aberra-
tions can be detected, as was shown recently.1-3 The resolution of
these genome‐wide approaches is mostly limited to the detection of- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
cense, which permits use, distribution and reproduction in any medium, provided
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What's already known about this topic?
• Noninvasive prenatal testing (NIPT) investigates cell‐free
DNA derived from the cytotrophoblast of chorionic villi.
• NIPT detects placental chromosome aberrations that may
be absent in the fetus.
• The majority of discordant NIPT results with a normal
fetal chromosome constitution, originates from confined
placental mosaicism.
What does this study add?
• For confirmation of abnormal genome‐wide NIPT
showing a microscopically visible structural chromosome
aberration, targeted diagnostic confirmatory testing,
only investigating the involved chromosome aberration,
should be avoided since the fetal chromosome
aberration may involve another chromosome or another
structural aberration type. Moreover, no karyotyping,
but a SNP array should be the method of first choice,
since the fetal chromosome aberration may be
submicroscopic whereas NIPT predicts a microscopically
visible aberration.
2 VAN OPSTAL ET AL.large, microscopically visible fetal chromosome aberrations of greater
than 10 to 15 Mb (eg, subchromosomal aberrations). The detection
of specific submicroscopic chromosome aberrations (eg,
microdeletions and microduplications, typically less than 5 Mb in size)
also have been described, and nowadays, these are sometimes
included in commercial NIPT‐kits.
Since the fetal part of the cell‐free DNA is derived from the
cytotrophoblast (CTB) of chorionic villi (CV), NIPT in fact detects pla-
cental chromosome aberrations. Although the chromosome constitu-
tion of placenta and fetus are expected to be the same in most
cases, it is known, mainly from CV studies, that discrepancies may
occur in 1% to 2% of CVS, at least in a high‐risk population.4 Confined
placental mosaicism (CPM) is the main reason for discordant NIPT
results.5 In a previous study, we showed that about 15% of rare auto-
somal trisomies (RAT, autosomal trisomies different from trisomies of
chromosomes 13, 18, and 21) that were detected with NIPT in preg-
nancies with abnormal first trimester combined (FTC) test results were
confirmed in the fetus, but the rest mainly showed to be confined to
the placenta.1 In contrast, in that same study, it was shown that 50%
(six out of 12) of large, microscopically visible (greater than 10 Mb),
structural chromosome aberrations that were detected with NIPT,
were confirmed in the fetus. This is in line with other papers showing
a confirmation rate of 50% to 62%.2,6
Follow‐up investigations after abnormal NIPT often are limited to
fetal, and depending on the NIPT result, also maternal cytogenetic
investigations, and if this reveals normal results, the NIPT is called
“false positive” or “discordant.” In most cases, it may then be assumed
that the chromosome aberration probably has a placental origin due to
the cytotrophoblastic origion of the cfDNA. However, proof is only
delivered if placental studies are performed. Since in most cases, an
amniocentesis instead of chorionic villus sampling (CVS) is recom-
mended according to a joint European Society of Human Genetics
(ESHG)/American Society of Human Genetics (ASHG) position state-
ment,7 only postnatal placental studies can proof a placental origin
of an aberration detected by NIPT.
In this paper, we present the results of placental follow‐up investi-
gations that were performed in three cases of abnormal NIPT showing
a structural chromosome aberration and another abnormal fetal karyo-
type involving a different structural aberration in an effort to elucidate
the observed discrepancies.2 | MATERIALS AND METHODS
We present three cases in which NIPT revealed a structural
chromosome aberration and in which fetal, placental, and maternal
cytogenetic follow‐up investigations during and after pregnancy were
performed in order to elucidate the discrepancies that were found
between the abnormal NIPT (partial duplication of 4q, a partial
deletion of 13q, and a partial deletion of 15q), and differently
abnormal fetal karyotype (with respectively a terminal deletion of 2q,
a segmental uniparental disomy of 13q and a partial duplication of
13q and 15q).In all cases, NIPT was performed as part of the Dutch Trident 1
study (Trident = Trial by Dutch laboratories for Evaluation of NIPT).
Trident 1 is a nationwide study in which NIPT is offered as an alterna-
tive option to invasive testing in patients at elevated risk for trisomy
21, 18, or 13, mostly through abnormal combined test results. A
license for the study was granted by the Minister of Health (11016‐
118701‐PG). All eight University Medical Centers participate in the
study.1,8 In our center alone, 2305 samples were processed during
the first 3 years (1 April 2014 to 1 April 2017). A total of 12 structural
chromosome aberrations were found, of which six were maternal in
origin and six had a fetal origin. Of the latter, three are presented in
this paper. The method that was used shortly involved genome‐wide
shallow massively parallel shotgun sequencing and genome‐wide anal-
ysis with WISECONDOR that has a resolution of approximately 15
Mb at a sequencing depth of about 10 to 12 million reads per sample.
Sex chromosomes were not analyzed.
Pretest counseling about the different options (invasive testing,
NIPT or no testing) was performed by a gynecologist at a University
Medical Center for prenatal diagnosis. Pregnant women were
informed on the nature of the NIPT test and the possible finding of
another chromosome aberration than the one for which they had an
increased risk (trisomy 21, 18, or 13). Posttest counseling in case of
an abnormal NIPT result was performed by a clinical geneticist.
Follow‐up fetal diagnostic investigations of uncultured amniotic
fluid (AF) during pregnancy and of uncultured umbilical cord blood
and buccal swab after birth were performed with SNP array (Illumina
VAN OPSTAL ET AL. 3Infinium_CytoSNP_850K genotyping array). In all cases, karyotyping or
fluorescent in situ hybridization (FISH) of AF cell cultures (in situ
method) were performed as well. In one case, buccal swab was inves-
tigated with FISH instead of SNP array. Cytogenetic investigations of
parental blood was performed with the same SNP array or with
karyotyping (depending on the chromosome aberration). To identify
the parental origin of the segmental uniparental disomy of chromo-
some 13 in case 2, SNPs were compared between mother and fetus
as described previously.9
Placental studies after birth involved the analysis of four CV biopsies
from four quadrants of the placenta. Both cell layers of CV, the CTB and
mesenchymal core (MC), were separated according to standard tech-
niques.9,10 After digestion of the MCwith collagenase, a part of the cell
suspension was cultured according to standard techniques (long‐term
cultured villi [LTC‐villi]) and a part was used for DNA isolation. Genomic
DNAwas also isolated from the CTB; 50 to 100 ng of DNAwas hybrid-
ized to the Illumina Infinium_CytoSNP_850K genotyping array. For
analysis, GenomeStudio (Illumina) and different versions ofNexusCopy
Number (BioDiscovery, versions 7.0 and higher) were used. In one case,
karyotyping of LTC‐villi was performed as well.
We collected clinical outcome data such as birthweight, gestational
age, and presence of congenital malformations in the three cases.3 | RESULTS
3.1 | Fetal and parental cytogenetic follow‐up
studies
The results of cytogenetic investigations of AF, cord blood, and/or
buccal swab after birth and of parental blood for confirmation of an
abnormal NIPT result are shown in Table 1. In all three cases, another
chromosome aberration than the one predicted by NIPT was found in
the fetus:
• In case 1, NIPT detected a duplication on 4q (Figure 1A), while the
fetus had a terminal deletion of 2q.
• In case 2 a deletion on 13q as detected with NIPT (Figure 1B)
showed to be a segmental uniparental isodisomy (UPiD) of mater-
nal origin of the terminal part of 13q in fetal cells. The PCCA gene
in this region was screened for mutations; none were found.
• In case 3 with a deletion of distal 15q in NIPT (Figure 1C), a mosaic
duplication of the distal part of the long arms of chromosomes 13
and 15 was found in AF cells.3.2 | Placental cytogenetic confirmatory testing
In an effort to elucidate the discordances between NIPT and prenatal
diagnosis, placental studies were performed. In all three cases, analysis
of placental CTB revealed the chromosome aberration that was found
with NIPT, while the chromosome constitution of the MC was repre-
sentative for that of the fetus:• Case 1:○ CTB: The duplication on chromosome 4q was indeed detected
in the CTB of two of four placental biopsies, which confirmed
the NIPT result. Moreover, a mosaic of different length dele-
tions of chromosome 2q (of 3, 4, and 56 Mb) was found
(Figure 2).
○ MC: The 10‐Mb 2q deletion that was seen in the fetus, and
which was absent in the CTB, was present in the MC of biop-
sies 2, 3, and 4, although at a low level as based on the B‐allele
frequency (BAF) profiles. The most prominent abnormal cell
line was a 3 Mb deletion (Figure 2).• Case 2:○ CTB: A mosaic terminal deletion of 13q was detected in the
CTB of all four placental biopsies. However, in each biopsy,
the deletion had a different length, ranging from 27.6 up to
61.1 Mb, with the other cell line showing a copy number neu-
tral region of homozygosity (ROH) of 25 Mb on 13q31.3q34.
The latter was also found in AF, cord blood, and buccal
mucosa as well as in all four MCs of placental villi (Figure 3).
Moreover, analysis of biopsy 3 also revealed a 19.2‐Mb
mosaic gain in 4p16.3p15.31.
○ MC: the MC of all four biopsies showed a 25‐Mb ROH that
was also seen in the fetus (Figure 3).• Case 3:○ CTB: The terminal deletion on chromosome 15 was confirmed
in the CTB of all four placental biopsies showing a mosaic
17 Mb deletion. In addition, a low mosaic duplication of 62.5
Mb, ranging from 15q11.2 to 15q25.3, was present as well
in all biopsies
○ MC: In the MC of the four biopsies, the same chromosome
constitution as in AF with a mosaic duplication of the terminal
36 Mb of 15q and the terminal 10 Mb of 13q was found, but
at a much higher level of between 60% and 80% depending on
the biopsy.3.3 | Clinical outcome
Clinical outcome data are shown in Table 1. In case 1 with a terminal
2q deletion, causing the well described 2q terminal deletion syndrome,
the pregnancy was terminated. In cases 2 and 3, with respectively a
segmental maternal UPiD13 (case 2) and low level mosaicism of partial
trisomies 13 and 15 (case 3), (apparently) healthy children were born
at an appropriate gestational age, both showing normal development
at the age of 2 years.4 | DISCUSSION
We present three cases in which extensive placental cytogenetic
studies revealed an explanation for the discordances between NIPT
showing a structural chromosome aberration and the abnormal fetal
karyotype involving a different chromosome aberration: In all three
T
A
B
LE
1
C
yt
o
ge
ne
ti
c
de
ta
ils
in
th
e
pr
es
en
te
d
ca
se
s:
ab
no
rm
al
N
IP
T
sh
o
w
in
g
a
st
ru
ct
ur
al
ch
ro
m
o
so
m
e
ab
er
ra
ti
o
n,
pr
en
at
al
an
d
po
st
na
ta
lf
o
llo
w
‐u
p
cy
to
ge
n
et
ic
st
u
di
es
,a
n
d
cl
in
ic
al
o
u
tc
o
m
e
In
di
ca
ti
o
n
fo
r
P
re
na
ta
l
T
es
ti
ng
,U
S
R
es
ul
ts
an
d
C
lin
ic
al
O
ut
co
m
e
N
IP
T
R
es
ul
t
Fe
ta
lR
es
ul
ts
(S
um
m
ar
y)
P
re
na
ta
l
C
yt
o
ge
ne
ti
c
R
es
ul
ts
R
es
ul
ts
of
P
la
ce
nt
al
St
ud
ie
s
an
d
P
os
tn
at
al
C
yt
og
en
et
ic
s
1
aF
T
S
D
S
1
:1
6
7
N
T
1
.9
m
at
er
na
l
ag
e:
3
8
y
N
o
rm
al
U
S
at
1
6
w
k,
at
ti
m
e
o
f
am
ni
o
ce
nt
es
is
T
O
P
at
1
9
6
/7
w
k
B
o
y,
2
9
0
g
du
p(
4
)
(q
2
5
q3
5
.2
)
de
l(2
)(q
3
7
.1
)
A
m
ni
o
ce
nt
es
is
1
6
w
k:
‐S
N
P
ar
ra
y:
de
no
vo
lo
ss
o
f
1
0
M
b
in
ba
nd
2
q3
7
.1
q3
7
.3
ar
r[
hg
1
9
]
2
q3
7
.1
q3
7
.3
(2
3
2
,7
1
7
,8
5
7
‐2
4
3
,0
4
8
,7
6
0
)x
1
d
n
‐K
ar
yo
ty
pe
:
4
6
,X
Y
,d
el
(2
)(q
3
7
.1
)[
2
3
]
P
ar
en
ts
N
o
rm
al
ka
ry
o
ty
pe
s:
4
6
,X
Y
an
d
4
6
,X
X
4
p
la
ce
n
ta
b
io
p
si
es
:
‐C
T
B
o
f
b
io
p
si
es
1
‐4
:
B
io
p
si
es
1
an
d
2
:
ch
r4
:1
0
0
%
d
u
p
4
q
ch
r2
:1
0
0
%
3
M
b
d
el
B
io
p
sy
3
:
ch
r4
:n
o
rm
al
ch
r2
:m
o
s
3
M
b
/4
M
b
/5
6
M
b
d
el
B
io
p
sy
4
:
ch
r4
:n
o
rm
al
ch
r2
:m
o
s
3
M
b
/4
M
b
d
el
‐M
C
o
f
b
io
p
si
es
1
‐4
:
B
io
p
sy
1
:
ch
r4
:n
o
rm
al
ch
r2
:1
0
0
%
3
M
b
d
el
B
io
p
sy
2
:
ch
r4
:
n
o
rm
al
ch
r2
:
m
o
s
2
M
b
/3
M
b
/1
0
M
b
d
el
B
io
p
si
es
3
an
d
4
:
ch
r4
:n
o
rm
al
ch
r2
:m
o
s
3
M
b
/1
0
M
b
d
el
2
aF
T
S
D
S
1
:1
8
,N
T
1
.9
m
m
m
at
er
na
l
ag
e
3
5
y
N
o
rm
al
U
S
at
1
8
6
/7
w
k,
3
3
4
/7
an
d
3
6
4
/7
w
k
H
ea
lt
hy
gi
rl
,b
o
rn
at
3
8
+
1
w
,3
1
2
0
g,
no
co
ng
en
it
al
m
al
fo
rm
at
io
ns
.
N
o
rm
al
de
ve
lo
pm
en
t
at
2
y
o
f
ag
e.
de
l(1
3
)(q
3
1
)
Se
gm
en
ta
l
m
at
U
P
iD
1
3
q3
1
.3
q3
4
A
m
ni
o
ce
nt
es
is
2
0
2
/7
w
k:
‐S
N
P
ar
ra
y:
~
2
5
M
b
R
O
H
o
n
1
3
q3
1
.3
q3
4
(m
at
er
n
al
se
gm
en
ta
l
U
P
iD
)
ar
r[
hg
1
9
]
1
3
q3
1
.3
q3
4
(9
0
2
5
2
6
7
1
_1
1
5
1
0
3
5
2
9
)x
2
hm
z
m
at
‐F
IS
H
o
n
cu
lt
ur
ed
ce
ll
cl
o
ne
s:
no
rm
al
nu
c
is
h
1
3
q1
4
(P
N
1
3
x2
),1
3
qt
er
(R
P
1
‐1
L1
6
x2
)[
4
].
is
h
1
3
q1
4
(P
N
1
3
x2
),1
3
qt
er
(R
P
1
‐1
L1
6
x2
)[
2
8
]
4
p
la
ce
n
ta
b
io
p
si
es
:
‐C
T
B
o
f
b
io
p
si
es
1
‐4
:
B
io
p
sy
1
:
m
o
s
6
1
.1
M
b
d
el
1
3
q
1
4
.3
q
3
4
a
B
io
p
sy
2
:
m
o
s
5
7
.2
M
b
d
el
1
3
q
2
1
.1
q
3
4
a
B
io
p
sy
3
:
(C
o
n
ti
n
u
es
)
4 VAN OPSTAL ET AL.
T
A
B
LE
1
(C
o
nt
in
ue
d)
In
di
ca
ti
o
n
fo
r
P
re
na
ta
l
T
es
ti
ng
,U
S
R
es
ul
ts
an
d
C
lin
ic
al
O
ut
co
m
e
N
IP
T
R
es
ul
t
Fe
ta
l
R
es
ul
ts
(S
um
m
ar
y)
P
re
na
ta
l
C
yt
o
ge
ne
ti
c
R
es
ul
ts
R
es
ul
ts
of
P
la
ce
nt
al
St
ud
ie
s
an
d
P
os
tn
at
al
C
yt
og
en
et
ic
s
P
ar
en
ts
A
rr
ay
no
rm
al
m
o
s
2
7
.6
M
b
d
el
1
3
q
3
1
.1
q
3
4
a
an
d
1
9
.2
M
b
m
o
sa
ic
ga
in
in
4
p
1
6
.3
p
1
5
.3
1
B
io
p
sy
4
:
m
o
s
3
0
M
b
d
el
1
3
q
3
1
.3
q
3
4
a
‐M
C
o
f
b
io
p
si
es
1
‐4
:
~
2
5
M
b
R
O
H
o
n
1
3
q
3
1
.3
q
3
4
C
o
rd
b
lo
o
d
an
d
b
u
cc
al
m
u
co
sa
:
~
2
5
M
b
R
O
H
o
n
1
3
q
3
1
.3
q
3
4
(m
at
U
P
iD
1
3
q
3
1
.3
q
3
4
)
ar
r[
h
g1
9
]
1
3
q
3
1
.3
q
3
4
(9
0
2
5
2
6
7
1
_1
1
5
1
0
3
5
2
9
)x
2
h
m
z
m
at
3
aF
T
S
D
S
1
:6
3
,N
T
1
.7
m
m
m
at
er
na
l
ag
e
2
7
y
N
o
rm
al
U
S
at
2
0
,2
3
6
/7
,2
7
6
/7
,a
nd
3
2
w
k
M
al
e
ne
w
bo
rn
at
3
8
+
5
w
k,
bi
rt
h
w
ei
gh
t
3
3
3
8
g
in
du
ce
d
la
bo
r
du
e
to
m
ild
pr
ee
cl
am
ps
ia
.
N
o
rm
al
de
ve
lo
pm
en
t
at
th
e
ag
e
o
f
2
y
de
l(1
5
)(q
2
5
)
M
o
sa
ic
ga
in
1
5
q2
2
.3
1
q2
6
.3
ga
in
an
d
m
o
sa
ic
1
3
q3
3
.2
q3
4
ga
in
A
m
ni
o
ce
nt
es
is
at
1
6
4
/7
w
k
‐S
N
P
ar
ra
y:
m
o
s
~
3
6
M
b
ga
in
o
f
1
5
q2
2
.3
1
q2
6
.3
an
d
~
1
0
M
b
ga
in
o
f
1
3
q3
3
.2
q3
4
(~
5
%
in
un
cu
lt
ce
lls
an
d
~
5
%
‐1
0
%
in
ce
ll
cu
lt
ur
es
)
ar
r[
hg
1
9
]
1
5
q2
2
.3
1
qt
er
(6
6
,6
1
2
,7
2
5
‐1
0
2
,4
6
1
,1
6
2
)x
2
~
3
,
1
3
q3
3
.2
qt
er
(1
0
5
,0
1
5
,2
2
3
‐1
1
5
,1
0
3
,5
2
9
)x
2
~
3
dn
‐K
ar
yo
ty
pi
ng
:
4
6
,X
Y
,a
dd
(1
3
)[
4
]/
4
6
,X
Y
[1
2
]
‐F
IS
H
:
1
5
qt
el
o
m
er
e
(R
P
1
‐1
5
4
P
1
)
an
d
1
5
q2
6
.2
(R
P
1
1
‐
7
8
4
A
9
an
d
R
P
1
1
‐3
3
7
N
1
2
):
ad
d(
1
3
)
=
t(
1
3
;1
5
)(q
3
4
;
q2
2
.3
1
)
in
8
/2
6
ce
ll
cl
o
ne
s
(3
1
%
)
P
ar
en
ts
A
rr
ay
no
rm
al
4
p
la
ce
n
ta
b
io
p
si
es
‐C
T
B
o
f
b
io
p
si
es
1
‐4
:
ch
r1
5
:
m
o
s
1
7
M
b
d
el
q
2
5
.3
q
2
6
.3
/6
2
.5
M
b
d
u
p
q
1
1
.2
‐
q
2
5
.3
ch
r1
3
:
n
o
rm
al
‐M
C
o
f
b
io
p
si
es
1
‐4
:
ch
r1
5
:
m
o
s
~
3
6
M
b
ga
in
o
f
1
5
q
2
2
.3
1
q
2
6
.3
ch
r1
3
:
m
o
s
~
1
0
M
b
ga
in
o
f
1
3
q
3
3
.2
q
3
4
K
ar
yo
ty
p
in
g
o
f
M
C
o
f
b
io
p
sy
1
:
4
6
,X
Y
,d
er
(1
3
)
(t
(1
3
;1
5
)
(q
3
4
;q
2
2
.3
1
))[
1
1
]/
4
6
,X
Y
[2
]
C
o
rd
b
lo
o
d
.
A
rr
ay
n
o
rm
al
B
u
cc
al
m
u
co
sa
F
IS
H
:
2
.5
%
3
si
gn
al
s
w
it
h
1
5
q
te
lp
ro
b
e
(1
0
/4
0
0
n
u
cl
ei
)
N
ot
e.
T
he
ch
ro
m
o
so
m
e
ab
er
ra
ti
o
n
as
fo
un
d
w
it
h
N
IP
T
(in
re
d
)w
as
co
nf
ir
m
ed
in
th
e
cy
to
tr
o
ph
o
bl
as
t
o
f
pl
ac
en
ta
lc
ho
ri
o
ni
c
vi
lli
,w
he
re
as
th
e
fe
ta
lc
h
ro
m
o
so
m
e
ab
er
ra
ti
o
n
,a
s
fo
u
n
d
in
am
n
io
ti
c
fl
u
id
(in
gr
ee
n
),
w
as
co
nf
ir
m
ed
in
m
es
en
ch
ym
al
co
re
o
f
pl
ac
en
ta
l
ch
o
ri
o
ni
c
vi
lli
.
A
bb
re
vi
at
io
ns
:a
F
T
S,
ab
no
rm
al
fi
rs
t
tr
im
es
te
r
sc
re
en
in
g;
ce
ll
cu
lt
,c
ul
tu
re
d
ce
lls
;c
hr
,c
hr
o
m
o
so
m
e;
C
T
B
,c
yt
o
tr
o
ph
o
bl
as
t;
de
l:
de
le
ti
o
n;
du
p,
d
up
lic
at
io
n
;m
at
U
P
iD
,m
at
er
n
al
u
n
ip
ar
en
ta
li
so
d
is
o
m
y;
M
C
,m
es
en
ch
y-
m
al
co
re
;
T
O
P
,t
er
m
in
at
io
n
o
f
pr
eg
na
nc
y;
un
cu
lt
,u
nc
ul
tu
re
d;
U
S,
ul
tr
as
o
un
d;
−
,n
o
t
av
ai
la
bl
e.
a T
he
o
th
er
ce
ll
lin
e
is
th
e
o
ne
w
it
h
ap
pr
o
xi
m
at
el
y
2
5
‐M
b
R
O
H
o
n
1
3
q3
1
.3
q3
4
th
at
w
as
al
so
de
te
ct
ed
in
M
C
,A
F
,c
o
rd
bl
o
o
d,
an
d
bu
cc
al
m
uc
o
sa
.
VAN OPSTAL ET AL. 5
FIGURE 1 WISECONDOR plots showing
the abnormal NIPT results in cases 1, 2, and 3.
(A) Case 1 with a duplication of part of 4q—
dup(4) (q25q35.2). (B) Case 2 showing a
terminal deletion of the long arm of
chromosome 13—del(13)(q31). C, Case 3 with
a terminal deletion of the long arm of
chromosome 15‐ del(15)(q25) [Colour figure
can be viewed at wileyonlinelibrary.com]
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FIGURE 2 LogR (A) and B‐allele frequency (BAF) (B) plots of chromosome 2 in different tissues of case 1: AF, amniotic fluid; CTB1, 2, 3, and 4,
cytotrophoblast of placental biopsies 1, 2, 3, and 4; MC1, 2, 3, and 4, mesenchymal core of placental biopsies 1, 2, 3, and 4. (A) Ideogram of
chromosome 2 and LogR plots: the LogR shows a 10‐Mb deletion in AF while the CTB and MC of all placental biopsies show a much smaller
deletion of 3 Mb. (B) Ideogram of chromosome 2 and BAF profiles showing a 100% deletion of 10 Mb in AF and a 100% 3 Mb deletion in CTB1,
MC1, and CTB2 confirming the LogR. It should be noted that in both CTB biopsies, a 5% to 10% maternal cell contamination is visible so that the
BAF profiles resemble that of an approximately 90% to 95% mosaic. Mosaicism of different lengths deletions (of 2, 3, 4, 10, and 56 Mb) is seen in
the other biopsies, with the 3‐Mb deletion being the predominant cell line. MC2 shows mosaicism of a 2‐, 3‐, and 10‐Mb deletion. Only knowledge
of the presence of a 10‐Mb deletion cell line in the conceptus reveals its presence in MC2. CTB3 shows a mosaic 3‐, 4‐, and 56‐Mb deletion. MC3
shows a mosaic 3‐ and 10‐Mb deletion. CTB4 shows mosaicism of a 3‐ and a 4‐Mb deletion. MC4 shows a mosaic 3‐ and 10‐Mb deletion [Colour
figure can be viewed at wileyonlinelibrary.com]
VAN OPSTAL ET AL. 7cases, the CTB of placental CV demonstrated the chromosome aberra-
tion found with NIPT, while the MC of the placental CV showed the
fetal chromosome aberration. This again proves the cytotrophoblasticorigin of the cf fetal DNA..11,12 Moreover, it again demonstrates that
the MC is better representative for the fetal chromosome constitution
due to the same embryonic origin.13
FIGURE 3 LogR (A) and B‐allele frequency (BAF) (B) plots of chromosome 13 in different tissues of case 2: AF, amniotic fluid; BM, buccal
mucosa; CB, cord blood; CTB1, 2, 3, and 4, cytotrophoblast of placental biopsies 1, 2, 3, and 4; MC1, 2, 3, and 4, mesenchymal core of
placental biopsies 1, 2, 3, and 4. (A) Ideogram of chromosome 13 and LogR plots in different tissues: AF, CB, BM, and MC1‐4: the LogR shows a
normal result. CTB1‐4 show a 61‐, 57‐, 27‐, and 30‐Mb deletion, respectively. (B) Ideogram of chromosome 13 and BAF profiles in different
tissues: AF, CB, BM, and MC1‐4: all BAF plots show a 25‐Mb ROH, fitting a segmental UPiD13. CTB1‐4 all show mosaicism for a 61‐, 57‐, 27‐,
and 30‐Mb deletion, respectively, with 25‐Mb segmental UPiD13 (in 13q31.3q34) in the normal cell line [Colour figure can be viewed at
wileyonlinelibrary.com]
8 VAN OPSTAL ET AL.In all three cases, chromosomal mosaicism involving multiple
abnormal cell lines that originated during early embryogenesis with
unequal distribution of abnormal cells over the different compart-
ments of CV and fetus explained the discordances. On a total of2305 blood samples from high‐risk pregnancies (cases with abnormal
FTC test results) that we investigated during the first 3 years of trident
1 in our center, 12 structural chromosome aberrations were found
with NIPT of which six were of maternal origin and six were fetal
VAN OPSTAL ET AL. 9(unpublished data from Erasmus MC). In half of these six fetal cases
(which are the three cases presented in this paper), we observed this
phenomenon of discordancy between NIPT results and fetal chromo-
some constitution, while in the other three cases, fetal karyotype and
NIPT result were concordant. So this does not seem to be an uncom-
mon phenomenon in case NIPT shows a subchromosomal aberration.
The use of an SNP array, which is very sensitive for detection of
low‐level mosaicism and other submicroscopic aberrations (eg, unipa-
rental disomy (UPD) and microdeletion/duplications) may contribute
to this high percentage of discrepancy. Nevertheless, our results war-
rant the use of a genome‐wide test over targeted testing for confirma-
tory cytogenetic investigations of CV or AF. For instance, FISH with a
4q‐probe in case 1 would never have revealed the fetal 2q‐terminal
deletion. Moreover, we believe that SNP array instead of karyotyping
or array CGH is the appropriate genome‐wide test since the segmental
UPD in case 2, would not be detected with the latter techniques, and
would potentially be of major clinical relevance if an imprinted chro-
mosome was involved. Apart from an increased risk for a recessive dis-
ease involving a gene in the ROH, there was no clinical effect to be
expected in this particular case of segmental UPD13. Also in case 1,
the terminal 10‐Mb deletion of 2q may be missed with karyotyping,
although its resolution is 5–10 Mb, but this will highly depend on
the quality of the chromosome preparations.
In all three placentas, complex mosaicism was found. In the cases
involving a deletion on chromosomes 2 (in the fetus and MC) and 13
(in all CTBs of the placenta), deletions of four different lengths were
found in the four placenta biopsies. Likewise, in the case with a termi-
nal duplication of 15q (in the fetus), a more proximal duplication was
found in the CTBs. These cytogenetic results probably demonstrate
the mitotic chromosome instability seen in cleavage stage embryos.14
It is striking that in the placenta of case 1 (deletion of chromosome 2),
most biopsies revealed mosaicism of different length deletions
whereas in the placenta of case 2 (deletion of chromosome 13), each
biopsy showed one deletion but all of a different length. Perhaps, this
demonstrates the instability of the chromosome 13 deletion during
early embryogenesis, which became stable during placental develop-
ment in case 2, whereas the reverse occurred in case 1, although we
admit that this is very speculative. Moreover, in one of the three pla-
centas (case 2), cytogenetic studies revealed an extra chromosome
aberration (a mosaic duplication of the short arm of chromosome 4)
in one CTB biopsy that was not seen prenatally (with NIPT or invasive
testing). This phenomenon of extra chromosome anomalies in the pla-
centa was recently described in 2/10 placentas that were investigated
in order to confirm abnormal NIPT involving a numerical chromosome
aberration.9
Unfortunately, it could not be investigated whether there is a cyto-
genetic association between the duplication of chromosome 4q that
was detected with NIPT and the terminal deletion of 2q (case 1).
The 4q duplication was only present in the CTB of two biopsies, and
these samples were not cultured but used entirely for DNA isolation
for SNP array (therefore, no chromosome preparations were available).
However, it is possible that the 4q was “captured” by the 2q terminal
deletion for telomere stabilization, at least in one of the earlyembryonic cells that was allocated to the CTB. It was recently shown
that distinct stabilizing events, telomere healing (eg, de novo telomere
addition mediated by telomerase) and telomere capture from a differ-
ent chromosome, resulting in a derivative chromosome, of the same
terminal deletion can occur in different early embryonic cells.15,16
The mosaic karyotype observed in case 2 with terminal deletions of
different lengths of chromosome 13q and with a segmental UPD of
the distal 25 Mb on 13q is another example of postzygotic telomere
stabilization through telomere capture as well as telomere healing in
different embryonic cells.15,16 Telomere capture here involved the
acquisition of a new telomere sequence from a chromatid from the
normal homologue, resulting in a maternal segmental UPiD13. Since
not a deletion, but only the segmental UPD was present in MC as well
as in the fetus (AF, cord blood, and buccal swab), and since both cell
lines were present in the CTB, an early repair in one of the first cleav-
age divisions (before differentiation in trophectoderm and inner cell
mass) of a meiotic terminal deletion of approximately 25 Mb is most
likely. Subsequently, only cells with the segmental UPiD were allo-
cated to the inner cell mass giving rise to 100% segmental UPiD13
in MC and fetus. The approximately 25‐Mb deletion cell line persisted
in the trophoblast and gave rise to larger deletions of approximately
27, 30, 57, and 61 Mb during further development.
The 2q deletion in case 1 could not be detected with our NIPT test
since in the CTB's of all CV biopsies, a much smaller deletion of 3 or 4
Mb was present in the majority of cells. Only low‐level mosaicism of a
larger 56‐Mb deletion was present in one of the biopsies, which prob-
ably did not result in a sufficient contribution to the cfDNA pool in
maternal plasma, so that it remained undetected with our NIPT
approach, characterized by a resolution of 10 to 15 Mb.17
In the era of NIPT, which investigates cfDNA that originates from
the CTB of CV, placental cytogenetic investigations are in the spot-
light again. Placental studies used to be frequently performed after
the introduction of CVS in the 80s of last century,18 and that led to
an exponential increase of our knowledge of CPM and its clinical rel-
evance. In our opinion, placental studies for confirmation of an abnor-
mal NIPT result are important for several reasons:
• If a placental origin is proven, another source for the abnormal
cfDNA, such as a maternal tumor, can be excluded.
• For reassurance of the parents that may be anxious after an abnor-
mal NIPT despite normal cytogenetic results from AF.
• For increased knowledge of the origin of abnormal NIPT and its
associated clinical impact.
• For better interpretation of abnormal results and therefore
improved pre‐as well as posttest counseling.
• Finally, for better insight into the true performance of the NIPT
test, probably reaching a positive predictive value of 100% if all
possible sources of the cfDNA would be investigated.
The main conclusion of this study is that the use of targeted cyto-
genetic investigations for confirmatory diagnostic testing of NIPT
showing a structural chromosome aberration should be avoided since
10 VAN OPSTAL ET AL.another chromosome aberration, even involving another chromosome,
may be present in the fetus. Moreover, also the use of karyotyping
should be discouraged and replaced by preferably SNP array since a
submicroscopic structural aberration or segmental UPD may be
present in the fetus even though the NIPT predicts a microscopically
visible chromosome aberration.
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